Список литературы

Поставить закладку

Кохно А.В., Паровичникова Е.Н., Михайлова Е.А. Алгоритмы обследования и протоколы лечения больных с различными формами миелодиспластических. Алгоритмы диагностики и протоколы лечения заболеваний системы крови: в двух томах. Под редакцией Е.Н. Паровичниковой. Том 1. – М: Практика, 2024: 551-589..
Ширин А.Д., Френкель М.А. Миелодиспластические синдромы // Клиническая онкогематология: руководство для врачей. Под ред. Волковой М.А.. 2-е изд., перераб. и доп. 2007. P. 502–551.
Garcia-Manero G. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. // Am. J. Hematol. 2015. Vol. 90, № 9. P. 831–841.
Malcovati L. et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. // Blood. 2013. Vol. 122, № 17. P. 2943–2964.
Greenberg P.L. et al. NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic syndromes. .Version 3.2024-July 25,2024. NCCN.org
Goldberg S.L. et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. // J. Clin. Oncol. 2010. Vol. 28, № 17. P. 2847–2852.
Swerdlow S.H. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, 2008. 439 p.
Swerdlow S.H. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC) / ed. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H T.J. 2017. 585 p.
Valent P. et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions // Oncotarget. Impact Journals, LLC, 2017. Vol. 8, № 43.
Gregg X.T., Reddy V., Prchal J.T. Copper deficiency masquerading as myelodysplastic syndrome. // Blood. 2002. Vol. 100, № 4. P. 1493–1495.
Irving J.A. et al. Element of caution: a case of reversible cytopenias associated with excessive zinc supplementation. // CMAJ. 2003. Vol. 169, № 2. P. 129–131.
Greenberg P.L., et al. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromesю Blood 2016; Vol. 128, №16: Р. 2096-2097.
Hellström-Lindberg E. et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. // Br. J. Haematol. 1997. Vol. 99, № 2. P. 344–351.
Seguier J. et al. Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review. // Autoimmun. Rev. 2019. Vol. 18, № 1. P. 36–42.
Wang H. et al. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome // Blood. 2002. Vol. 100, № 12. P. 3897–3902.
Yoshida Y. et al. Co-occurrence of monoclonal gammopathy and myelodysplasia: a retrospective study of fourteen cases. // Int. J. Hematol. 2014. Vol. 99, № 6. P. 721–725.
Mufti G.J. et al. Immunological abnormalities in myelodysplastic syndromes I. SERUM IMMUNOGLOBULINS AND AUTOANTIBODIES // Br. J. Haematol. 1986. Vol. 63, № 1. P. 143–147.
De Hollanda A. et al. Systemic and immune manifestations in myelodysplasia: A multicenter retrospective study // Arthritis Care Res. 2011. Vol. 63, № 8. P. 1188–1194.
Wolach O., Stone R. Autoimmunity and Inflammation in Myelodysplastic Syndromes // Acta Haematol. 2016. Vol. 136, № 2. P. 108–117.
Means R.T. Pure red cell aplasia/ Hematologt Am Soc hematol Educ Programm. 2016 (1): P. 51–56
Hara R. et al. Fetal hemoglobin level predicts lower-risk myelodysplastic syndrome. Int J Hematol. 2023; Vol. 117, №5: P.684-693.
Fong T. et al. Copper deficiency: An important consideration in the differential diagnosis of myelodysplastic syndrome // Haematologica. 2007. Vol. 92, № 10. P. 1429–1430.
Thakral B., Saluja K., Eldibany M. Zinc-induced copper deficiency: a diagnostic pitfall of myelodysplastic syndrome. // Pathology. 2014. Vol. 46, № 3. P. 246–248.
Komrokji R.S.. et al. Autoimmunne diseases and myelodysplastic syndrome. // Am J Hematol. 2016. Vol. 91, № 5. E. 280–3.
Bennett J.M., Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: Recommendations for a standardized approach // Haematologica. 2009. Vol. 94, № 2. P. 264–268.
Goasguen J.E. et al. Quality control initiative on the evaluation of the dysmegakaryopoiesis in myeloid neoplasms: Difficulties in the assessment of dysplasia. // Leuk. Res. 2016. Vol. 45. P. 75–81.
Mufti G.J. et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. // Haematologica. 2008. Vol. 93, № 11. P. 1712–1717.
Patnaik M.M., Tefferi A. Refractory anemia with ring sideroblasts and RARS with thrombocytosis. // Am. J. Hematol. 2015. Vol. 90, № 6. P. 549–559.
Двирнык В.Н., с соав. Цитологическая и цитохимическая диагностика сидеробластных анемий. Гематология и трансфузиология, 2024. 69 (1). Стр. 80-88
Greenberg P.L. et al. Revised international prognostic scoring system for myelodysplastic syndromes // Blood. 2012. Vol. 120, № 12. P. 2454–2465.
Gupta R. et al. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. // Br. J. Haematol. 2007. Vol. 139, № 2. P. 265–268.
Gyan E., Dreyfus F., Fenaux P. Refractory thrombocytopenia and neutropenia: a diagnostic challenge. // Mediterr. J. Hematol. Infect. Dis. 2015. Vol. 7, № 1. P. e2015018.
Mallo M. et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. // Leukemia. 2011. Vol. 25, № 1. P. 110–120.
Olney H.J., Le Beau M.M. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes. // Leuk. Res. 2007. Vol. 31, № 4. P. 427–434.
Rogers H.J. et al. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. // Haematologica. 2014. Vol. 99, № 5. P. 821–829.
Schanz J. et al. New comprehensive cytogenetic scoring system for MDS and oligoblastic AML after MDS // J. Clin. Oncol. 2012. Vol. 30, № 8. P. 820–829.
Steensma D.P. et al. Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia? // Leuk. Res. 2003. Vol. 27, № 3. P. 235–242.
Paulsson K., Johansson B. Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes. // Pathol. Biol. (Paris). 2007. Vol. 55, № 1. P. 37–48.
Bigoni R. et al. Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. // Haematologica. 2001. Vol. 86, № 4. P. 375–381.
Fu B. et al. Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. // Mod. Pathol. 2014. Vol. 27, № 5. P. 681–689.
Huang T.C. et al. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies // Leukemia. Nature Publishing Group, 2008. Vol. 22, № 3. P. 544–550.
Maschek H. et al. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. // Eur. J. Haematol. 1992. Vol. 48, № 4. P. 208–214.
Orazi A. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases // Pathobiology. 2007. Vol. 74, № 2. P. 97–114.
Yue G. et al. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. // Leuk. Res. 2008. Vol. 32, № 4. P. 553–558.
Della Porta M.G. et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. // J. Clin. Oncol. 2009. Vol. 27, № 5. P. 754–762.
Orazi A. et al. Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. // Am. J. Clin. Pathol. 1997. Vol. 107, № 3. P. 268–274.
Verburgh E. et al. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. // J. Clin. Oncol. 2003. Vol. 21, № 2. P. 273–282.
Alhan C. et al. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes. // Br. J. Haematol. 2014. Vol. 167, № 1. P. 100–109.
Alhan C. et al. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes // Cytom. Part B - Clin. Cytom. Wiley-Liss Inc., 2014. Vol. 86, № 3. P. 207–215.
Bardet V. et al. Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. // Haematologica. 2015. Vol. 100, № 4. P. 472–478.
Porta M.G.D. et al. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: Results of a European LeukemiaNET study // Haematologica. 2012. Vol. 97, № 8. P. 1209–1217.
Della Porta M.G. et al. Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia. // Haematologica. 2014. Vol. 99, № 1. P. e8-10.
Kern W. et al. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. // Cancer. 2010. Vol. 116, № 19. P. 4549–4563.
Haferlach T. et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes // Leukemia. 2014. Vol. 28, № 2. P. 241–247.
Malcovati L. et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts // Blood. American Society of Hematology, 2015. Vol. 126, № 2. P. 233–241.
List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: P. 1456- 1465.
57. Ingram W. et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. // Leukemia. 2006. Vol. 20, № 7. P. 1319–1321.
Malcovati L., Rumi E., Cazzola M. Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms // Haematologica. Ferrata Storti Foundation, 2014. Vol. 99, № 11. P. 1650–1652.
Savage S.A., Walsh M.F. Myelodysplastic Syndrome, Acute Myeloid Leukemia, and Cancer Surveillance in Fanconi Anemia // Hematology/Oncology Clinics of North America. W.B. Saunders, 2018. Vol. 32, № 4. P. 657–668.
Della Porta M.G. et al. Predictive factors for the outcome of allogeneic transplantation in patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System (IPSS-R). // Blood. 2014. P. 2333–2342.
Аксельрод Б.А. et al. Клиническое использование эритроцитсодержащих компонентов донорской крови // Гематология и трансфузиология. 2018. Vol. 63, № 4. P. 372–435.
Bruzzone M.G. et al. CT and MRI of brain tumors // Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2012. Vol. 56, № 2. P. 112–137.
Greenberg P. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. // Blood. 1997. Vol. 89, № 6. P. 2079–2088.
Malcovati L. et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). // Haematologica. 2011. Vol. 96, № 10. P. 1433–1440.
Cheson B.D. et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. // Blood. 2006. Vol. 108, № 2. P. 419–425.
Hoeks M.P.A. et al. Impact of red blood cell transfusion strategies in haemato-oncological patients: a systematic review and meta-analysis. // Br. J. Haematol. 2017. Vol. 178, № 1. P. 137–151.
Rose C. et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). // Leuk. Res. 2010. Vol. 34, № 7. P. 864–870.
Neukirchen J. et al. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry. // Leuk. Res. 2012. Vol. 36, № 8. P. 1067–1070.
Taher A. T.et al New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study. //Am J Hematol.2017, 92(5): 420-428.
Tartaglione I. et al., Two-year long safety and efficacy of deferasirox film-coated in patients with talassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study. // Exp Hematol Oncol . 2020 Aug 10:9:20.
Mainous A.G. et al. The impact of chelation therapy on survival in transfusional iron overload: a meta -analysis of myelodysplastic syndrome. Br J Haematol. 2014; 167:720-723.
Delforge M. et al. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. // Leuk. Res. 2014. Vol. 38, № 5. P. 557–563.
Remacha Á.F. et al. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. // Ann. Hematol. 2015. Vol. 94, № 5. P. 779–787.
Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelobysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: result of a prospective randomized phase III trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009; 114:2393-2400
Park S. et al. Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis. // Br. J. Haematol. 2016. Vol. 174, №5. P. 730–747.
Platzbecker U. et al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes // Leukemia. Nature Publishing Group, 2017. Vol. 31, № 9. P. 1944–1950.
Gascon P. et al. Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols // Leukemia Research, 2019, 81, Р. 35–42.
Hellström-Lindberg E. et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. // Blood. 1998. Vol. 92, № 1. P. 68–75.
Balleari E. et al. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. //Ann Hematol. 2006 Mar;85(3):174-80.
Park S. et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: The GFM experience // Blood. American Society of Hematology, 2008. Vol. 111, № 2. P. 574–582.
Toma A., et al. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. // Leukemia, 2016, 30(4):897-905.
List A.F., et al. Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. J Clin Oncol. 2021 Jan 13;39(9):1001–1009.
Greenberg P.L. et al. A randomized controlled trial of romiplostim in patients with low- or 17. P. 3163–3170.intermediate-risk myelodysplastic syndrome receiving decitabine. // Leuk. Lymphoma. 2013. Vol. 54, № 2. P. 321–328.
Kantarjian H.M. et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. // Blood. 2010. Vol. 116, № 17. P. 3163–3170.
Sekeres M.A. et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. // Cancer. 2011. Vol. 117, № 5. P. 992–1000.
Giagounidis A. et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. // Cancer. 2014. Vol. 120, № 12. P. 1838–1846.
Oliva E.N. et al. Eltrombopag for the Treatment of Thrombocytopeults on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial // Blood. 2015. Vol. 126, № 23.
Oliva E.N. et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. // Lancet. Haematol. 2017. Vol. 4, № 3. P. e127–e136.
Mittelman M. et al. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. // Lancet. Haematol. 2018. Vol. 5, № 1. P. e34–e43.
Stahl M. et al. Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. // Haematologica. 2019.
Giagounidis A. et al. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.// Eur J Haematol 2014;93:429-438.
Fenaux P. et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study // Lancet Oncol. 2009. Vol. 10, № 3. P. 223–232.
Kantarjlan H. et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study // Cancer. 2006. Vol. 106, № 8. P. 1794–1803.
Silverman L.R. et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B // J. Clin. Oncol. 2002. Vol. 20, № 10. P. 2429–2440.
Kantarjian H. et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia // Blood. 2007. Vol. 109, № 1. P. 52–57.
Pan T. et al. Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies // Leuk. Res. Elsevier Ltd, 2018. Vol. 71. P. 13–24.
Ye L. et al. Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone // J. Cancer Res. Clin. Oncol. Springer Verlag, 2017. Vol. 143, № 5. P. 873–882.
Ye X.-N. et al. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms. // Leuk. Lymphoma. 2016. Vol. 57, № 6. P. 1311–1318.
Кохно А.В., Паровичникова Е.Н., Савченко В.Г. Протокол сочетанного применения гипометилирующих препаратов с низкодозной полихимиотерапией у больных МДС из группы высокого риска, ОМЛ из МДС, МДС/ОМЛ после апластической анемии, МДС/ОМЛ после лучевой и цитостатической терапии по поводу другого заболеван // Алгоритмы диагностики и протоколы лечения заболеваний системы крови. НМИЦ Гематологии. Под ред. В.Г. Савченко. 2018. P. 829–840.
Zwierzina H. et al. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group// Leukemia. 2005 Nov; 19(11):1929-33.
Estey E.H. et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. // Blood. 2001. Vol. 98, № 13. P. 3575–3583.
Robak T. et al. Efficacy and toxicity of low-dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. // Neoplasma. 2003. Vol. 50, № 3. P. 172–175.
Omoto E. et al. Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. // Leukemia. 1996. Vol. 10, № 4. P. 609–614.
Oliansky D.M. et al. The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Myelodysplastic Syndromes: An Evidence-Based Review // Biology of Blood and Marrow Transplantation. Elsevier Inc., 2009. Vol. 15, № 2. P. 137–172.
Sorror M.L. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. // Blood. 2005. Vol. 106, № 8. P. 2912–2919.
Hilarius D.L. et al. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. // Support. Care Cancer. 2012. Vol. 20, № 1. P. 107–117.
Belay Y., Yirdaw K., Enawgaw B. Tumor Lysis Syndrome in Patients with Hematological Malignancies // Journal of Oncology. Hindawi Limited, 2017. Vol. 2017.
Averbuch D. et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: Guidelines of the 4th European conference on Infections in Leukemia (ECIL-4, 2011) // Haematologica. 2013. Vol. 98, № 12. P. 1836–1847.
Heinz W.J. et al. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) // Annals of Hematology. Springer Verlag, 2017. Vol. 96, № 11. P. 1775–1792.
Loth K. et al. Infectious Complications Associated with the Use of Antithymocyte Globulin in Reduced Intensity Allogeneic Transplants // Antithymocyte Globul. Reduc. Intensity Allogeneic Transplants. Chemother. 2012. Vol. 2012, № 4. P. 106.
Alkharabsheh O.A. et al. Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. // Ann. Hematol. 2019. Vol. 98, № 2. P. 331–337.
Stanworth S.J. et al. Platelet refractoriness--practical approaches and ongoing dilemmas in patient management. // Br. J. Haematol. 2015. Vol. 171, № 3. P. 297–305.
Weisdorf S.A. et al. Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow transplantation. // Transplantation. 1987. Vol. 43, № 6. P. 833–838.
Arends J. et al. ESPEN guidelines on nutrition in cancer patients // Clin. Nutr. Churchill Livingstone, 2017. Vol. 36, № 1. P. 11–48.
Камельских Д.В., с соавт. Трансфузии донорской крови и (или) ее компонентов у взрослых пациентов с гематологическими заболеваниями. Сопроводительная терапия при лечении заболеваний системы крови. Под ред. Паровичниковой Е.Н., Галстяна Г.М. М: Практика, 2024: 387-406.
Bourgeois E. et al. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases. // Leukemia. 2001. Vol. 15, № 6. P. 950–953.
Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies. // Am. J. Phys. Med. Rehabil. 2011. Vol. 90, № 5 Suppl 1. P. S88-94.
European Physical and Rehabilitation Medicine Bodies Alliance. White book on physical and rehabilitation medicine in Europe (3th Edition): Chaper 1: Definition an conceps of PRM // Eur. J. Phys. Rehabil. Med. 2018. Vol. 54, № 2. P. 156–165.
Porta M. Della et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome // Haematologica. 2011. Vol. 96, № 3. P. 441–449.
Swerdlow S.H., et al. WHO classification of Tumors of Haematopoietic and Lymphoid Tissues, 2017, pp. 81-96.
Patnaik MM, Timm MM, Vallapureddy R, et al. Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. Blood Cancer J. 2017;7(7):e584.
Pophali PA, Timm MM, Mangaonkar AA, et al. Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia. Blood Cancer J. 2019;9(9):65
Akbar A. et al., A Systematic Review and Meta-Analysis of Luspatercept for Anemia Treatment in Low Risk Myelodysplastic Syndrome with Ring Sideroblast Subtype in Phase II and Phase III Clinical Trials. Blood 2020; 136 (Supplement 1): 40–41
Fenaux P. et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med. 2020;382(2):140-151
Platzbecker U. et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet. 2023;402(10399):373-385
Amitai I et al. Efficacy of Luspatercept in Low-Risk Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis. Blood 2023; 142 (Supplement 1): 6487.
Rabian F. et al. Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study, Blood, 2020.
Melody M., et al. Lenalidomide Is Effective Treatment Option for Patients with Refractory Anemia with Ring Sideroblastsand Trombocytosis. Blood, 2018,132,4383
Naqvi K., et al. Characteristics and Role Lenalidomide Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Trombocytosis. Blood, 2018, 132, 5513.
Komrokji R., et al. Treatment outcomes for patients with myelodysplastic/ myeloproliferative neoplasms ring sideroblasts and thrombocytosis. Leuk. Lypphoma, 2022, 63, 199-204.
Xu R. et al. Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: A meta-analysis and systematic review. Hematology 2021, 26, 312-320.
Santini V., et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia, 2018, 32, 413-418.
Mangaonkar A.A., et al. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinical Cancer Center study of 135 consecutive patients. Leukemia, 2020,34, 656-661.
Gerke V.B., et al. Definitions, Biology, and Current Therapeutic Landscape of Myelodisplastic/ Myeloproliferative Neoplasms. Cancer, 2023, 15, 3815.
Desikan S., et al. A phase I study of the combination of venetoclax and azacitidine in relapse/refractory higher risk myelodysplastic syndrome (MDS). Blood 2021; 138(Suppl 1) :3704.
Ball B.J., et al. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv 2020; 4(13):2866—2870.
Du Yu, et al. The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis. Hematology 2023; 28(1):2198098.
El-Cheikh J. et al. Venetoclax: a new partner in the novel treatment era for acute myeloid leukemia and myelodysplastic syndrome. Clin Hematol Int 2023; 5(2–3):143—154.
Zeidan А.М., et al. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Am J Hematol 2023; 98(2):272—281.
Wei A.H., et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol 2019; 37(15):1277—1284.
Fenaux P. et al. Low-Dose Cytosine Arabinoside in Adult Chronic Myelomonocytic Leukemia. J Clin Oncol (1987) 5:1129–30.
Wattel E. et al. A Randomized Trial of Hydroxyurea Versus VP16 in Adult Chronic Myelomonocytic Leukemia. Groupe Francais Des Myelodysplasies and European CMML Group. Blood (1996) 88:2480–7.
Itzykson R. et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network. J Clinical Oncology, 2022; Vol. 41, №10.
Zhang L., et al. A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients. Front Pharmacol. 2024;15:1265840.
Kröger N., et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Br. J. Haematol. 2002;118:67–73.
Kerbauy D.M.B., et al. Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. Biol. Blood Marrow Transplant. 2005;11:713–720.
Sharma P., et al. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. Leuk. Lymphoma. 2017;58:872–881.
Pophali P., et al. Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. Blood Cancer J. 2020;10:121.
Gagelmann N., et al. A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. Blood Adv. 2021;5:1760–1769.
Such E., et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121:3005–3015.
Elena C., et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128:1408–1417.
Pophali P., et al. Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients. Am J Hematol. 2018 Nov;93(11):1347-1357.
Сопроводительная терапия при лечении заболеваний системы крови. Практическое руководство/ под. ред. Е.Н.Паровичниковой, Г.М. Галстяна. М.: Практика, 2024, 512с.
Кохно А.В., с соавт. Эффективность терапии циклоспорином А у больных миелодиспластическим синдромом. Терапевтический архив, 2010, том 82, №8, стр. 48-53.
Bernard E. et al. Molecular International Prognosis Scoring System for Myelodysplastic Syndromes. NEJM Evid2022;1:Evidoa2200008. IPSS-M Web calculator: https://mds-risk-model.com
Кохно А.В., Паровичникова Е.Н., Терапия миелодиспластических новообразований и миелодиспластических/миелопролиферативных новообразований из группы высокого риска. Алгоритмы диагностики и протоколы лечения заболеваний системы крови: в двух томах. Под редакцией Е.Н. Паровичниковой. Том 1. – М: Практика, 2024: 590-618.
Miller K.B., et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study*, Ann Hematol (1992) 65:162-168.
Buckley S.A., et al. Prediction of Adverse Events during Intensive Induction Chemotherapy for Acute Myeloid Leukemia or High-Grade Myelodysplastic Syndromes Am J Hematol. 2014 Feb 24;89(4):423–428.
Heisel R.W., et al. Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine. Leuk Lymphoma. 2017; 58(11): 2565-2572.
Ball B., et al. Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. Blood Adv, 2018; 2(16): 2063–2071.
Buccisano F., et al. Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a «Gruppo Romano Mielodisplasie (GROM)» multicenter study. Ann Hematology, 2016, Vol.95, P. 1059-1065.
Tatarelli C., et al. Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study. Ann Hematol. 2014; Vol. 93, №8, Р. 1413-20.
Mundle S., et al. An assessment of erythroid response to epoetin α as a single agent versus in combination with granulocyte– or granulocyte-macrophage–colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach// Cancer, 2009, Vol.115, №4, Р. 706-715.
Клинические рекомендации «Острые миелоидные лейкозы», 2020.
Wei A.H., et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood, 2020, Vol. 135 (24), Р. 2137-2145.
DiNardo C.D., et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies Am J Hematol. 2018;93: P.401–407
Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996;87:4076-4081.
Кохно А.В., Паровичникова Е.Н., Михайлова Е.А. Савченко В.Г. Алгоритмы обследования и протоколы лечения больных с различными формами миелодиспластических сндромов. Алгоритмы диагностики и протоколы лечения заболеваний системы крови: в двух томах. Под редакцией В.Г. Савченко. Том 1. –НМИЦ Гематологии, 2018: 441-478..

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница

Приложение А3. Справочные материалы, включая соответствие показаний к применению и противопоказаний, способов применения и доз лекарственных препаратов, инструкции по применению лекарственного препарата +

Приложение Б. Алгоритмы действий врача

Приложение В. Информация для пациента

Приложение Г1-ГN. Шкалы оценки, вопросники и другие оценочные инструменты состояния пациента, приведенные в клинических рекомендациях +

Данный блок поддерживает скрол*